DIRS.INFO The most relevant business & tech news

☆ Dengue Spreads Fast in Brazil Prompting Emergency Health Measures
▼ + stars: | 2024-02-07 | by ( Feb. | At P.M. | ) www.usnews.com time to read: +3 min

By Ricardo Brito and Anthony BoadleBRASILIA (Reuters) - Dengue fever has surged in Brazil's hot rainy season, forcing health authorities to take emergency measures and start mass vaccination against the mosquito-borne illness. In the first five weeks of this year 364,855 cases of infection have been reported, the Health Ministry said, four times more than dengue cases in the same period of 2023. The rapid spread of dengue has caused 40 confirmed deaths, the ministry said, and a further 265 are being investigated. The Health Ministry has set up an emergency center to coordinate operations against dengue across Brazil. Dengue fever symptoms include a high fever, headache, vomiting, muscle and joint pains, and an itching skin rash.

Persons: Ricardo Brito, Anthony Boadle BRASILIA, Qdenga, Tedros Adhanom, Anthony Boadle, Angus MacSwan Organizations: Reuters, Health Ministry, Federal, Army, Brazilian Air Force, World Health Organization, WHO, El Locations: Brazil, Minas Gerais, Brasilia, Brasilia ., Rio de Janeiro, Europe, America

☆ Dengue Will 'Take Off' in Southern Europe, US, Africa This Decade, WHO Scientist Says
▼ + stars: | 2023-10-06 | by ( Oct. | At A.M. | ) www.usnews.com time to read: +4 min

By Jennifer RigbyLONDON (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Earlier this week, the WHO recommended Takeda Pharmaceuticals' Qdenga vaccine for children aged 6 to 16 in areas where the infection is a significant public health problem. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Jennifer Rigby LONDON, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration Locations: United States, Europe, Africa, Asia, Latin America, Bangladesh, Vietnam, Saharan Africa, EU

[1/2] Mosquitoes are seen on stagnant water on the roadside during countrywide dengue infection, in Dhaka, Bangladesh, August 24, 2023. REUTERS/Mohammad Ponir Hossain/File Photo Acquire Licensing RightsCompanies Takeda Pharmaceutical Co Ltd FollowLONDON, Oct 6 (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Mohammad Ponir Hossain, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: REUTERS, Takeda Pharmaceutical, World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration, Thomson Locations: Dhaka, Bangladesh, United States, Europe, Africa, Asia, Latin America, Vietnam, Saharan Africa, EU

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

☆ Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
▼ + stars: | 2023-07-27 | by ( ) www.reuters.com time to read: +2 min

Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said. That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv. The company held its forecast for full-year operating profit at 349 billion yen. Analysts expect 481.1 billion yen on average for the year.

Persons: Takeda, Rocky Swift, Tom Hogue, Robert Birsel Organizations: Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson Locations: Japan, United States, U.S

☆ New Dengue Vaccine Approved in Europe
▼ + stars: | 2022-12-08 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Takeda Pharmaceutical’s dengue vaccine, Qdenga, could generate peak annual sales of at least $700 million, the Tokyo-based company said. European health regulators cleared a new dengue vaccine from Takeda Pharmaceutical Co., a decision that could pave the way for its use around the world against the devastating mosquito-borne virus. The European Commission approved the two-dose shot in people ages 4 years and older, Takeda said Thursday.

Search resuls for: "Qdenga"

6 mentions found